Market access, HTA and HEOR careers: what the terms actually mean

Market access

Market access brings together evidence, pricing, reimbursement, policy and stakeholder strategy. Teams assess the decision environment, define the value proposition, prepare for payer engagement and coordinate the route from regulatory approval to funded use.

Roles can be national, regional or global. Responsibilities may include access strategy, payer research, value communication, pricing governance, reimbursement submissions, negotiation and launch sequencing. The exact scope depends heavily on the healthcare system and company model.

Health technology assessment

Health technology assessment, or HTA, is a structured evaluation of the clinical and economic value of a health technology. Organisations such as NICE assess evidence against a defined methodological and decision framework. Other jurisdictions use different processes, comparators, perspectives and requirements.

HTA work can involve evidence synthesis, indirect comparison, economic modelling, budget impact, patient evidence, submission writing and responses to technical questions. A recommendation is not the same as regulatory approval: the two decisions answer different questions.

Health economics and outcomes research

HEOR develops evidence about outcomes, resource use, costs, quality of life and value. Work may include economic models, real-world evidence, patient-reported outcomes, burden-of-illness studies and evidence synthesis.

HEOR specialists often support both development and access planning. Their analyses must make assumptions, uncertainty and limitations transparent. Submission-grade economic work requires appropriate validation and expert review; a narrative summary is not a substitute for a functioning model.

How the teams work together

Market access defines the decision and stakeholder strategy. HEOR generates or interprets evidence needed to support that strategy. HTA specialists translate the evidence into a jurisdiction-specific submission and manage appraisal requirements. Medical, regulatory, clinical, epidemiology and commercial colleagues contribute evidence and implementation context.

For candidates, the important distinction is what you personally owned. State whether you designed the study, managed the vendor, interpreted results, authored a submission section, led payer engagement or made a pricing recommendation.

Follow one decision through the three disciplines

Take a hypothetical new medicine. Market access defines the payer problem and route; HEOR develops or analyses comparative outcomes, costs and uncertainty; the HTA workstream applies the relevant jurisdiction’s scope and methods to a submission. The hand-offs should retain the same population, comparators and evidence identity.

Now label who selected the comparator, built or validated the analysis, authored the submission, engaged the payer and approved the final position. This exercise prevents a broad project description from being mistaken for personal experience across every discipline.

A role-evidence checklist

For each example, capture jurisdiction, product stage, decision problem, population, comparator, evidence type, controlled output, your action, reviewer or governance forum and outcome. Identify assumptions and uncertainty instead of reporting only the favourable conclusion.

If you managed a specialist vendor, say what you commissioned, how you challenged methods and which decision you retained. If you performed the analysis, state the method and validation boundary. These are complementary forms of experience, but they should remain distinguishable.

Sources and further reading

Authoritative sources support the regulated or employment context. The practical framework and interpretation are original PTTF editorial work.

1. NICE health technology evaluations: the manual — NICE
2. Evidence in health technology evaluation — NICE
3. Economic evaluation in health technology evaluation — NICE